You are using an outdated browser. Please upgrade your browser to improve your experience.

Tbio
DSE
Dermatan-sulfate epimerase

Protein Summary
Description
Converts D-glucuronic acid to L-iduronic acid (IdoUA) residues. The protein encoded by this gene is a tumor-rejection antigen. It is localized to the endoplasmic reticulum and functions to convert D-glucuronic acid to L-iduronic acid during the biosynthesis of dermatan sulfate. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy. Mutations in this gene cause inmusculocontractural Ehlers-Danlos syndrome. Alternative splicing results in multiple transcript variants. A related pseudogene has been identified on chromosome 9, and a paralogous gene exists on chromosome 18. [provided by RefSeq, Apr 2016]
Uniprot Accession IDs
Gene Name
Ensembl ID
  • ENST00000331677
  • ENSP00000332151
  • ENSG00000111817
  • ENST00000452085
  • ENSP00000404049
  • ENST00000644252
  • ENSP00000494147

Symbol
  • SART2
  • DSEP
  • DSEPI
  • SART2
  • EDSMC2
  • SART-2
  • DS-epi1
Illumination Graph
Knowledge Table
Most Knowledge About
Knowledge Value (0 to 1 scale)
transcription factor binding site profile
0.76
gene perturbation
0.71
transcription factor
0.69
transcription factor perturbation
0.68
cellular component
0.64


Protein Classes
No PANTHER Classes or DTO Classes found
IDG Development Level Summary
Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 42.08   (req: < 5)
Gene RIFs: 5   (req: <= 3)
Antibodies: 74   (req: <= 50)
Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 42.08   (req: >= 5)
Gene RIFs: 5   (req: > 3)
Antibodies: 74   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 4
Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0
Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0